 |
BioWorld-Insight-2011-02-21
Making the Financing Side as Creative as the Research Side
First in Class vs. Best in Class; Not the Same Old R&D Debate
It would be easy to view Merck & Co. Inc.'s recent decision to bail on two novel-target collaborations with Galapagos NV as a troubling sign that the industry is shying away from innovation and putting more investment dollars behind the safer, tried-and-true mechanisms of earlier blockbusters. (See BioWorld Today, Feb. 9, 2011.)